Fifty years after thalidomide; what role for drug regulators?

被引：19

作者：

Eichler, Hans-Georg ^{[1
]}

Abadie, Eric ^{[1
,2
]}

Baker, Mary ^{[1
]}

Rasi, Guido ^{[1
]}

机构：

[1] EMA, London E14 4HB, England

[2] Agence Francaise Securite Sanit Prod Sante, St Denis, France

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 74卷 / 05期

关键词：

D O I：

10.1111/j.1365-2125.2012.04255.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：731 / 733

页数：3

相关论文

共 3 条

[1]

[Anonymous], BEN RISK METH PROJ R

[2] Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [J].

Beasley, B. Nhi ;

Unger, Ellis F. ;

Temple, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1788-1790

[3] Balancing the Benefits and Risks of Inhaled Long-Acting Beta-Agonists - The Influence of Values [J].

Kramer, Judith M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (16) :1592-1595